Alpha DNA Investment Management’s Ryder R Stock Holding History

Alpha DNA Investment Management’s Portfolio R Stock Details R Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,973	Closed	-$601K	–	195
2022 Q3	$601K	Buy	+7,973	New	+$607K	0.5%	80
2021 Q2	–	Sell	-79	Closed	-$5K	–	521
2021 Q1	$5K	Sell	79 -7	-8%	-$485	0.01%	376
2020 Q4	$5K	Buy	+86	New	+$4.79K	0.01%	375

Other funds holding R

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HVCM

HG Vora Capital Management New York $197M AUM 17.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alpha DNA Investment Management's R Position: Q4 2022 in Review

Alpha DNA Investment Management sold out of Ryder (R) in Q4 2022, closing a stake of 7,973 shares — an estimated $601K sold.

Alpha DNA Investment Management first reported a position in R in Q4 2020 and held it in 3 quarters. The position peaked at $601K in Q3 2022. 356 funds tracked by Wall St. Rank hold R as of Q4 2022.

Alpha DNA Investment Management reported no remaining Ryder position as of Q4 2022 after selling out during the quarter.
Alpha DNA Investment Management sold 7,973 Ryder shares in Q4 2022, an estimated $601K.
Alpha DNA Investment Management first reported a position in Ryder in Q4 2020 and held it in 3 quarters.
Alpha DNA Investment Management's Ryder position peaked at $601K in Q3 2022.
356 funds tracked by Wall St. Rank held Ryder as of Q4 2022.

Based on Alpha DNA Investment Management's 13F filing for Q4 2022, filed 27 Jan 2023.